Lobeline (Piperidine Alkaloid · Nicotinic Partial Agonist · Lobelia · DAT Inhibition)

Compound	Lobeline
Chemical class	Alkaloid — Piperidine (2,6-Disubstituted piperidine; Lobelia alkaloid)
CAS	90-69-7
Primary source	Lobelia inflata (Indian tobacco / pukeweed) dried whole plant
Key applications	Nicotinic partial agonist, smoking cessation research, expectorant, dopamine reuptake inhibition
Claim strength	Moderate
Typical form	Lobelia inflata extract standardised to lobeline; lobeline isolate
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Lobelia (the genus, named after Flemish botanist Matthias de l’Obel). Lobeline is the primary piperidine alkaloid of Lobelia inflata, structurally distinct from nicotine but pharmacologically similar — it is a partial agonist at neuronal nicotinic acetylcholine receptors (nAChRs) with highest affinity for α4β2 subtype. Traditional use: Lobelia inflata (Indian tobacco) was used by Native American tribes (particularly Cherokee) as an emetic and respiratory herb — the common name “pukeweed” reflects its emetic properties at higher doses. In 19th-century American botanical medicine (Thomson school), Lobelia was a cornerstone expectorant and antispasmodic. Lobeline preparations were historically marketed for smoking cessation in the early 20th century (“Bantron”, “Nikoban”) before FDA regulatory action. Research trajectory: Lobeline had decades of research as a nicotinic partial agonist for smoking cessation, but Cochrane meta-analysis (Stead & Hughes 2012) concluded insufficient evidence for smoking cessation efficacy. Current research interest has shifted to lobeline’s dopamine reuptake transporter (DAT) inhibition — relevant to stimulant addiction research and ADHD. It remains an active research compound for drug abuse treatment. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.

---

Evidence for Lobeline Applications

Smoking cessation (historical and limited clinical): Multiple small trials with lobeline preparations showed modest smoking cessation benefit, but the Cochrane review (2012) of 6 trials found no significant benefit over placebo at 6-month follow-up. The research consensus is that lobeline’s nicotinic partial agonism is insufficient for smoking cessation compared to nicotine NRT or cytisine. Current clinical interest in lobeline for smoking cessation is low. Claim strength: Moderate (mechanism; limited clinical efficacy).

Dopamine reuptake inhibition (addiction research): Lobeline inhibits the vesicular monoamine transporter 2 (VMAT2) and dopamine reuptake transporter (DAT), reducing dopamine release in the nucleus accumbens — attenuating the dopamine surge that drives methamphetamine and nicotine reward. This mechanism is being explored for treatment of stimulant addiction. Lobeline analogues (lobelane) with improved DAT selectivity are under preclinical development. Claim strength: Moderate (preclinical; no approved application).

Expectorant and bronchodilatory: Traditional lobeline uses for respiratory conditions have mechanistic support — lobeline activates β2-adrenergic receptors and stimulates respiratory mucus clearance via vagal afferent activation. Used in some traditional respiratory preparations in Eastern Europe and Asia. Claim strength: Moderate (traditional; limited clinical).

---

Dosage & Formulator Specification

Historical smoking cessation doses: 0.5–2 mg lobeline per tablet, up to 8 tablets/day. Current regulatory status for smoking cessation products containing lobeline is complex — FDA removed lobeline from the OTC smoking cessation monograph in 1993 due to insufficient efficacy evidence. For respiratory/expectorant applications, Lobelia inflata herb preparations at traditional doses (0.1–0.5 g dried herb/dose) are used in traditional herbal medicine. IMPORTANT: Lobeline has a narrow therapeutic/toxic margin — at doses only modestly above therapeutic, nausea, vomiting, bronchospasm, and cardiovascular depression occur. All lobeline-containing preparations require precise dose control. Contraindicated in pregnancy and with cardiac conditions.

---

Frequently Asked Questions — Lobeline

Is lobeline the same as nicotine in pharmacological effect?
Both are nicotinic partial agonists but differ in potency, receptor selectivity, and pharmacokinetics. Nicotine is a full agonist at α4β2 nAChRs; lobeline is a partial agonist at α4β2 with lower intrinsic efficacy, producing less dopamine release than nicotine. This reduced dopamine release is why lobeline was theorised to work for smoking cessation — reducing nicotine reward — but the clinical evidence did not confirm meaningful efficacy.

Why is Lobelia sometimes called “Indian tobacco”?
Native American communities used Lobelia inflata in ceremonial and medicinal contexts in ways that resembled tobacco use — including smoking preparations and respiratory applications. The botanical appearance and alkaloid content of Lobelia produce some similar physiological effects to tobacco at low doses. However, Lobelia is not related to tobacco (Nicotiana) botanically; the name reflects functional similarity rather than botanical relationship.

Can lobeline cause lung damage?
Lobeline is a potent respiratory stimulant at sub-emetic doses but can cause bronchospasm and respiratory depression at higher doses — the same vagal stimulation that drives expectorant effects can, at excessive doses, produce adverse bronchospasm. Historical reports of Lobelia toxicity (emetism, respiratory compromise) are from overdose scenarios. At controlled traditional doses, Lobelia is not associated with lung damage, and historical long-term users (Thomson botanical medicine practitioners) do not show documented pulmonary toxicity.

Is lobeline being developed as a pharmaceutical for addiction treatment?
Lobeline and its analogues (lobelane, GZ-793A) are in preclinical development for methamphetamine use disorder and tobacco addiction via VMAT2/DAT inhibition. No lobeline-based compound has reached Phase III trials for addiction treatment. The research programme is active but not yet producing clinical-stage candidates for approved use.

Related compounds: Nicotine, Cytisine, Piperine, Anabasine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery